Moxifloxacin Tad (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these enzymes prevents bacterial cell division, leading to bacterial death and providing broad‑spectrum antibacterial activity.

The specific dose and duration of Moxifloxacin Tad are determined by the prescribing clinician based on the infection type, severity, patient characteristics, and local guidelines. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

The safety of moxifloxacin in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxifloxacin offers a broader spectrum against both Gram‑positive and Gram‑negative bacteria and has enhanced activity against atypical respiratory pathogens compared with older fluoroquinolones. It also has a lower propensity for certain drug‑resistance mechanisms, but safety considerations such as QT prolongation remain similar across the class.

Moxifloxacin Tad should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and sources of heat to maintain its stability and potency.

Moxifloxacin Tad is taken orally, usually as a tablet, with or without food as directed by the prescriber. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.

Serious risks include tendon rupture, especially in the Achilles tendon, QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated diarrhea. Patients should be educated to seek immediate medical attention if these events occur.

Moxifloxacin Tad is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should be used with caution in individuals with a history of tendon disorders, prolonged QT interval, or severe renal impairment, and it is generally avoided in pregnant or breastfeeding women unless absolutely necessary.